Research

Hormonal

Setmelanotide, a melanocortin-4 receptor (MC4R) agonist, produces significant weight loss and reduced hunger in patients with severe obesity linked to specific genetic deficiencies (POMC, PCSK1, LEPR, BBS, Alström, SRC1, SH2B1).

For individuals with severe obesity caused by specific genetic mutations (like POMC or LEPR deficiencies), Setmelanotide is a highly effective treatment that significantly reduces body weight and hunger. It requires regular injections, and patients should be prepared for common side effects like skin darkening and injection site reactions, which are generally manageable. This treatment is specifically indicated for genetic forms of obesity, not general weight loss.

GoodSupportsHIGH confidence
Our results support the use of setmelanotide in treating severe obesity... The mean difference in percentage (% mean) weight loss for the pooled data was −6.91%... and the mean percentage difference (% mean) in the decrease in the maximum hunger score for the grouped data was −35.6%.
Bárbara Ferraz Barbosa et al. · Journal of Personalized Medicine · 2023

Why this rating

Meta-analysis of 12 studies with GRADE rating of 'high' certainty for weight loss, though heterogeneity was high.

Source

Efficacy and Safety of Setmelanotide, a Melanocortin-4 Receptor Agonist, for Obese Patients: A Systematic Review and Meta-Analysis

Bárbara Ferraz Barbosa et al. · Journal of Personalized Medicine · 2023

DOI 10.3390/jpm13101460

Meta-analysis · 12 studiesCited 29×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →